Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million for the quarter, compared to the consensus ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Soleno Therapeutics (SLNO – Research Report) and ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vera Therapeutics (VERA – Research Report), ...

Rhythm Pharmaceuticals has a twelve month low of $35.17 and a twelve month high of $68.58. The company has a market capitalization of $3.38 billion, a PE ratio of -12.35 and a beta of 2.30. Hedge ...

Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...

In this article, we are going to take a look at where Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) stands against other worst high-risk high-reward growth stocks to buy. Is the Tariff Solution ...

During today's Nintendo Direct, Rhythm Heaven Groove, a brand-new installment in the Rhythm Heaven series, was announced. The rhythm-game series hasn't seen a new title since 2015's Rhythm Heaven ...

In a recent transaction, Joseph Shulman, the Chief Technical Officer of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), sold 10,468 ...

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...

Milestone Pharmaceuticals said on Friday that the U.S. health regulator had declined to approve its nasal spray to treat a ...